SYRE
Spyre Therapeutics, Inc. · Healthcare · Market cap $8.2B
Insiders sold $16.9M net in the last 90 days ·4 sellers, 0 buyers· 12 of 12 sales under Rule 10b5-1 plans· latest Form 4 filed Oct 3, 2026
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$443.0M
reported sales (SEC code S)
Unique Insiders
7
in the rolling window
Latest filing
Oct 3, 2026
King-Jones Heidy
Spyre Therapeutics, Inc. (SYRE) has 32 SEC Form 4 filings (116 transaction rows) in the rolling window, disclosed by 7 distinct insiders. Most recent filing: Oct 3, 2026.
Inside the rolling window, 7 insiders at Spyre Therapeutics, Inc. reported no open-market purchases and 34 open-market sales totaling $443.0M. The most active filer is Chief Executive Officer Turtle Cameron with 12 filings. Insiders have net sold $438.3M over the trailing 6 months. The most recent open-market filing is a sale of 28,933 shares by See Remarks King-Jones Heidy, dated Oct 1, 2026, worth $2.6M.
- Industry:Biotechnology
- CEO:Cameron Turtle
- Employees:125
- HQ:Waltham, MA, US
- IPO:2016-04-07
| Source | |||||||
|---|---|---|---|---|---|---|---|
| See Remarks | Sale | 28,933 | $2.6M | Oct 3 | +0.2% | SEC ↗ | |
| Chief Executive Officer | Sale | 15,000 | $1.4M | Oct 3 | +0.2% | SEC ↗ | |
| Chief Financial Officer | Sale | 17,500 | $1.6M | Oct 3 | — | SEC ↗ | |
| Chief Financial Officer | Sale | 7,500 | $689K | Oct 3 | — | SEC ↗ | |
King-Jones HeidyFirst filing | See Remarks | Sale | 27,999 | $2.4M | Sep 4 | — | SEC ↗ |
King-Jones HeidyFirst filing | See Remarks | Sale | 400 | $36K | Sep 4 | — | SEC ↗ |
| Chief Financial Officer | Sale | 7,500 | $655K | Sep 4 | — | SEC ↗ | |
| Chief Financial Officer | Sale | 18,232 | $1.6M | Sep 4 | — | SEC ↗ | |
| Chief Executive Officer | Sale | 15,000 | $1.3M | Sep 4 | — | SEC ↗ | |
Albers Jeffrey W.First in 8 months | Director | Sale | 23,000 | $2.4M | Aug 11 | — | SEC ↗ |
| Chief Financial Officer | Sale | 7,500 | $717K | Aug 6 | — | SEC ↗ | |
| Chief Executive Officer | Sale | 15,000 | $1.4M | Aug 6 | — | SEC ↗ | |
| Chief Financial Officer | Sale | 7,500 | $658K | Jul 3 | — | SEC ↗ | |
| Chief Medical Officer | Sale | 8,334 | $731K | Jul 3 | — | SEC ↗ | |
| Chief Executive Officer | Sale | 15,000 | $1.3M | Jul 3 | — | SEC ↗ | |
| Chief Financial Officer | Sale | 15,000 | $1.3M | Jun 27 | — | SEC ↗ | |
| Director | Sale | 4,684,781 | $399.7M | Jun 24 | — | SEC ↗ | |
| Director | Sale | 20,000 | $2.0M | Jun 24 | — | SEC ↗ | |
| Chief Medical Officer | Sale | 8,333 | $625K | Jun 4 | — | SEC ↗ | |
| Chief Executive Officer | Sale | 15,000 | $1.1M | Jun 4 | — | SEC ↗ | |
| Chief Financial Officer | Sale | 7,500 | $533K | Jun 4 | — | SEC ↗ | |
| Director | Sale | 80,000 | $6.0M | May 9 | — | SEC ↗ | |
| Chief Financial Officer | Sale | 12,500 | $892K | May 2 | — | SEC ↗ | |
| Chief Medical Officer | Sale | 78,333 | $5.6M | May 2 | — | SEC ↗ | |
| Chief Executive Officer | Sale | 15,000 | $1.1M | May 2 | — | SEC ↗ |
Earnings: last 7 quarters
Frequently asked questions
How many SEC Form 4 insider filings does SYRE have?
Spyre Therapeutics, Inc. (SYRE) has 32 SEC Form 4 filings (116 transaction rows) in the rolling 365-day window, disclosed by 7 distinct insiders. Most recent filing: Oct 3, 2026.
When was the most recent SEC Form 4 filing for SYRE?
The most recent Form 4 filing for SYRE on Tracefour is dated Oct 3, 2026.
Who is the most active insider at SYRE?
The most active SEC Form 4 filer at SYRE in the rolling window is Chief Executive Officer Turtle Cameron, with 12 filings.
What is the net insider flow at SYRE over the last 6 months?
Over the trailing 180 days, insiders at SYRE have net sold $438.3M based on SEC Form 4 disclosures.
What is the total insider buy and sell value at SYRE in the current window?
Inside the rolling window, insiders at SYRE bought $0 and sold $443.0M based on SEC Form 4 filings.
Can I get alerts for SYRE insider trading?
Yes. Tracefour sends a free email when a new SEC Form 4 purchase or sale is filed at Spyre Therapeutics, Inc. (SYRE). Alerts are set per company from the page itself, there is no paid tier, and each email links to the original filing on SEC EDGAR.
Related companies
Spyre Therapeutics, Inc. is in the Healthcare sector.